PLK1 and head and neck squamous cell carcinoma: While sensitivity differed between cell models, at least two of the three HNSCC models were sensitive (>60% inhibition at 500 nM) to a group of six drugs including adavosertib (WEE1), alisertib (AURKA), danusertib (AURKA and AURKB), prexasertib (CHK1), reversine (MPS1), and BI 2536 (PLK1).